Click here to close now.

SYS-CON MEDIA Authors: Liz McMillan, Dana Gardner, Elizabeth White, Carmen Gonzalez, PagerDuty Blog

News Feed Item

Veloxis Pharmaceuticals publishes Annual Report 2013

HORSHOLM, Denmark, March 5, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) ('Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2013. The annual report has been prepared in accordance with International Financial Reporting Standards as adopted by the EU and additional Danish disclosure requirements for annual reports of listed companies.

This company announcement should be read in conjunction with Veloxis' annual report 2013 published separately today.

Full Year 2013 Highlights

  • Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus® for the prevention of organ rejection in kidney transplant recipients.
  • Granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The designation is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases.
  • Dosing of the first patient in ASERTAA (A Study of Extended Release Tacrolimus in African-Americans) Phase IIIb study of Envarsus® in kidney transplant recipients. The ASERTAA study is designed to compare the pharmacokinetics (PK) of Envarsus®, a once-daily tacrolimus tablet, to generic twice daily tacrolimus capsules in stable African-American renal transplant patients.
  • The trade name for LCP-Tacro™ is Envarsus®.
  • Envarsus® successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002. The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf® as the comparator, met its primary efficacy and primary safety endpoints.
  • The European Medicines Agency (EMA) accepted for review the company's Marketing Authorization Application (MAA) to market Envarsus® for the prevention of organ rejection in kidney transplant patients in the European Union. Veloxis expects the decision from the European Union in 2014.
  • Data from the STRATO study demonstrates the potential for Envarsus® to improve tacrolimus-induced tremors in stable kidney transplant patients.
  • Submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market Envarsus® for the prevention of organ rejection in kidney transplant patients in the European Union.
  • During 2013, Veloxis recognized deferred revenue of DKK 38.2 million as revenue compared to DKK 6.9 million in 2012. Deferred revenue consist of up-front and milestone payments under Veloxis' distribution agreement with Chiesi Farmaceutici S.p.A. and is recognized in the income statement based on planned development periods.
  • Research and development costs decreased by DKK 64.2 million, or by 30.5%, from DKK 210.7 million in 2012 to DKK 146.5 million in 2013. Research and development costs are mainly attributable to the phase III trial in Envarsus® (de novo patients, Study 3002). The reduction in cost between the two periods is mainly related to effect from the executed restructuring and discontinuation of other pipeline activities in May 2012.
  • Administrative expenses decreased by DKK 9.1 million or by 24.7%, from DKK 36.9 million in 2012 to DKK 27.8 million in 2013. The reduction in cost is attributable to the continued focus of reducing overall cost, combined with the effect of the reduction in the number of employees that took place in May 2012.
  • During 2013, Veloxis recognized DKK 139.3 million in net loss compared to DKK 262.7 million in 2012. The net loss is better than management's expectations for 2013 as reported on 13 November 2013 in connection with the third quarter interim report, which projected a net loss of DKK 160 - 190 million. The positive deviation is mainly driven by the granted orphan drug status which has reduced regulatory costs.
  • As per 31 December 2013, the balance sheet reflects cash and cash equivalents of DKK 328.7 million compared to DKK 496.8 million as per 31 December 2012. The decrease in cash position reflects the changes in operating activities in 2013. The cash position is in line with management's expectations for 2013, which projected a cash position at the end of 2013 of DKK 310 - 340 million.

Conference Call
On 5 March, 2014, Veloxis' Management will host a conference call, at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM ET (New York).

To access the live conference call, please dial one of the following numbers:
+45 32 72 80 18 Denmark
+44 (0) 1452 555 131 UK
+1 866 682 8490 USA
Access code 1728236

Following the conference call, a recording will be available on the company's website www.veloxis.com. A presentation will be available on Veloxis' website (under 'Investors').


 


Financial Highlights













DKK'000

2013

2012

2011

2010

2009








Income Statement






Revenue

38,148

6,868

-

1,496

2,476

Research and development costs

(146,512)

(210,739)

(222,053)

(210,426)

(210,140)

Administrative expenses

(27,771)

(36,889)

(47,814)

(52,198)

(62,381)

Operating loss before restructuring cost

(136,135)

(240,760)

(269,867)

(261,128)

(270,045)

Restructuring cost

-

(21,462)

-

(10,894)

(9,489)

Operating loss

(136,135)

(262,222)

(269,867)

(272,022)

(279,534)

Net financial income / (expenses)

(4,426)

(850)

16,048

(759)

8,540

Loss before tax

(140,561)

(263,072)

(253,819)

(272,781)

(270,994)

Tax for the period

1,250

363

1,193

(1,425)

-

Net loss for the period

(139,311)

(262,709)

(252,626)

(274,206)

(270,994)








Balance Sheet






Cash and cash equivalents

328,652

496,834

297,727

531,519

333,429

Total assets

348,863

509,271

320,927

562,906

379,269

Share capital

166,057

165,932

452,543

452,543

56,568

Total equity

279,042

409,737

255,900

498,238

317,281

Investment in property, plant and equipment

1,055

260

2,981

2,583

11,043








Cash Flow Statement






Cash flow from operating activities

(157,747)

(205,870)

(234,637)

(238,148)

(251,158)

Cash flow from investing activities

(1,055)

169,712

(169,778)

(2,658)

(11,011)

Cash flow from financing activities

(3,227)

404,304

(5,948)

440,014

729

Cash and cash equivalents at period end

328,652

496,834

297,727

531,519

333,429








Financial Ratios






Basic and diluted EPS (DKK)

(0.08)

(0.43)

(0.56)

(2.84)

(4.80)

Weighted average number of shares

1,660,353,248

607,511,489

452,542,480

96,707,708

56,443,701

Average number of employees (FTEs)

26

48

52

59

93

Assets/equity

1.25

1.24

1.25

1.13

1.20

 

Fourth Quarter 2013 Highlights

  • Research and development cost were realized at DKK 29.5 million compared to DKK 41.9 million in same period in  2012, and DKK 35.2 million in the previous quarter.
  • Administrative expenses were realized at DKK 6.5 million compared to DKK 10.2 million in same period in 2012, and DKK 6.7 million in the previous quarter.
  • Operating loss amounted to DKK 23.8 million, while net loss was realized at DKK 24.7 million.

Financial Highlights








Quarterly Numbers in DKK




















Q4

Q3

Q2

Q1

Q4

Q3

Q2

Q1



2013

2013

2013

2013

2012

2012

2012

2012



DKK'000

DKK'000

DKK'000

DKK'000

DKK'000

DKK'000

DKK'000

DKK'000











Income Statement









Revenue

12,206

12,206

6,868

6,868

6,868

-

-

-

Research and development costs

(29,546)

(35,247)

(42,772)

(38,947)

(41,890)

(49,362)

(56,639)

(62,848)

Administrative expenses

(6,457)

(6,703)

(6,834)

(7,777)

(10,235)

(6,961)

(9,462)

(10,231)

Operating loss before restructuring cost

(23,797)

(29,744)

(42,738)

(39,856)

(45,257)

(56,323)

(66,101)

(73,079)

Restructuring cost

-

-

-

-

-

-

(21,462)

-

Operating loss

(23,797)

(29,744)

(42,738)

(39,856)

(45,257)

(56,323)

(87,563)

(73,079)

Net financial income / (expenses)

(1,425)

(4,655)

(2,253)

3,907

(2,302)

993

2,051

(1,592)

Loss before tax

(25,222)

(34,399)

(44,991)

(35,949)

(47,559)

(55,330)

(85,512)

(74,671)

Tax for the period

522

242

241

244

1,034

(223)

(130)

(318)

Net loss for the period

(24,700)

(34,157)

(44,750)

(35,704)

(46,525)

(55,553)

(85,642)

(74,989)











Balance Sheet









Cash and cash equivalents

328,652

380,179

399,743

456,216

496,834

86,683

152,720

213,786

Total assets

348,863

388,982

409,371

465,939

509,271

99,590

167,799

235,187

Share capital

166,057

166,057

166,057

166,057

165,932

45,254

45,254

452,543

Total equity

279,042

302,307

334,686

377,276

409,737

42,103

98,968

182,545

Investment in property,









plant and equipment

1,055

-

-

-

43

-

126

91











Cash Flow Statement









Cash flow from operating activities

(47,417)

(14,040)

(51,165)

(45,125)

(399)

(62,707)

(62,400)

(80,364)

Cash flow from investing activities

(1,055)

-

-

-

56,619

59,486

24,174

29,433

Cash flow from financing activities

(319)

(401)

(2,555)

48

410,149

(3,450)

(1,085)

(1,310)

Cash and cash equivalents









at period end

328,652

380,179

399,743

456,216

496,834

86,683

152,720

213,786











Financial Ratios









Basic and diluted EPS

(0.01)

(0.02)

(0.03)

(0.02)

(0.08)

(0.12)

(0.19)

(0.17)

Weighted average number of shares

1,660,572,426

1,660,572,426

1,660,572,426

1,659,683,537

607,511,489

452,542,480

452,542,480

452,542,480

Average number of employees (FTEs)

23

26

27

29

33

49

55

55

Assets/equity

1.25

1.29

1.22

1.24

1.24

2.37

1.70

1.29

Outlook for 2014
Veloxis is expecting an operating loss of DKK 60 - 90 million compared to the realized operating loss of DKK 136 million in 2013. Net loss is expected to be in the range of DKK 55 - 85 million compared to the net loss of DKK 139 million in 2013. As of 31 December 2013, the Company's cash position equaled DKK 329 million and the Company's 31 December 2014 cash position is expected to be in the range of DKK 230 - 270 million.

The above estimates are subject to possible changes primarily due to the timing of regulatory approvals and associated milestone payments along with variation of clinical activities and fluctuating exchange rates.

Important events following the balance sheet date
On 8 January, Veloxis announced that United States Patent and Trademark Office had issued a Notice of Allowance for U.S. Application Serial Number 13/167,420, a patent which covers the diurnal-independent administration of Envarsus®.

For more information, please contact:

Veloxis Pharmaceuticals A/S




John D. Weinberg

Executive Vice President & CCO

Mobile: +1 732 321 3208

Email: [email protected]  

Johnny Stilou

Executive Vice President & CFO

Phone: + 45 21 227 227

Email: [email protected]

About Envarsus® and tacrolimus
Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after transplantation. Envarsus® is an investigational drug that is being developed as a once-daily tablet version of tacrolimus with improved bioavailability, consistent pharmacokinetic performance and reduced peak-to-trough variability when compared to currently approved tacrolimus products. Transplant patients need to maintain a minimum blood level of tacrolimus for the prevention of transplant allograft rejection, but excessive levels may increase the risk of serious side effects such as nephrotoxicity, tremor, diabetes, high blood pressure, and opportunistic infections. Therefore, tacrolimus levels need to be managed carefully, and transplant patients are typically obliged to make frequent visits to the hospital for monitoring and dose adjustments after receiving a new organ.

About Veloxis Pharmaceuticals
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is Envarsus® for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. 

For further information, please visit www.veloxis.com.

SOURCE Veloxis Pharmaceuticals

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Hosted PaaS providers have given independent developers and startups huge advantages in efficiency and reduced time-to-market over their more process-bound counterparts in enterprises. Software frameworks are now available that allow enterprise IT departments to provide these same advantages for developers in their own organization. In his workshop session at DevOps Summit, Troy Topnik, ActiveState’s Technical Product Manager, will show how on-prem or cloud-hosted Private PaaS can enable organ...
The WebRTC Summit 2014 New York, to be held June 9-11, 2015, at the Javits Center in New York, NY, announces that its Call for Papers is open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 16th International Cloud Expo, @ThingsExpo, Big Data Expo, and DevOps Summit.
SYS-CON Media announced today that @WebRTCSummit Blog, the largest WebRTC resource in the world, has been launched. @WebRTCSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. @WebRTCSummit Blog can be bookmarked ▸ Here @WebRTCSummit conference site can be bookmarked ▸ Here
SYS-CON Events announced today that Cisco, the worldwide leader in IT that transforms how people connect, communicate and collaborate, has been named “Gold Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Cisco makes amazing things happen by connecting the unconnected. Cisco has shaped the future of the Internet by becoming the worldwide leader in transforming how people connect, communicate and collaborat...
WSM International is launching a DevOps services division that offers assessment, consulting and implementation to large enterprises and organizations with complex infrastructures. This is the first independent services company to create a dedicated practice to help organizations looking to transition to the DevOps model. The concept of DevOps is to blend information technology (IT) software development with operations to optimize the computing infrastructure according to the specific needs of ...
SYS-CON Events announced today that the DevOps Institute has been named “Association Sponsor” of SYS-CON's DevOps Summit, which will take place on June 9–11, 2015, at the Javits Center in New York City, NY. The DevOps Institute provides enterprise level training and certification. Working with thought leaders from the DevOps community, the IT Service Management field and the IT training market, the DevOps Institute is setting the standard in quality for DevOps education and training.
Wearable technology was dominant at this year’s International Consumer Electronics Show (CES) , and MWC was no exception to this trend. New versions of favorites, such as the Samsung Gear (three new products were released: the Gear 2, the Gear 2 Neo and the Gear Fit), shared the limelight with new wearables like Pebble Time Steel (the new premium version of the company’s previously released smartwatch) and the LG Watch Urbane. The most dramatic difference at MWC was an emphasis on presenting we...
SYS-CON Events announced today that robomq.io will exhibit at SYS-CON's @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. robomq.io is an interoperable and composable platform that connects any device to any application. It helps systems integrators and the solution providers build new and innovative products and service for industries requiring monitoring or intelligence from devices and sensors.
Temasys has announced senior management additions to its team. Joining are David Holloway as Vice President of Commercial and Nadine Yap as Vice President of Product. Over the past 12 months Temasys has doubled in size as it adds new customers and expands the development of its Skylink platform. Skylink leads the charge to move WebRTC, traditionally seen as a desktop, browser based technology, to become a ubiquitous web communications technology on web and mobile, as well as Internet of Things...
Today, IT is not just a cost center. IT is an enabler and driver of business. With the emergence of the hybrid cloud paradigm, IT now has increasingly more capabilities to create new strategic opportunities for a business. Hybrid cloud allows an organization to utilize multi-tenant public clouds, dedicated private clouds, bare metal hosting, and the associated support and services for the right use cases through an on-demand, XaaS model. This model of IT creates tremendous opportunities for busi...
Docker is an excellent platform for organizations interested in running microservices. It offers portability and consistency between development and production environments, quick provisioning times, and a simple way to isolate services. In his session at DevOps Summit at 16th Cloud Expo, Shannon Williams, co-founder of Rancher Labs, will walk through these and other benefits of using Docker to run microservices, and provide an overview of RancherOS, a minimalist distribution of Linux designed...
Business as usual for IT is evolving into a “Make or Buy” decision on a service-by-service conversation with input from the LOBs. How does your organization move forward with cloud? In his general session at 16th Cloud Expo, Paul Maravei, Regional Sales Manager, Hybrid Cloud and Managed Services at Cisco, discusses how Cisco and its partners offer a market-leading portfolio and ecosystem of cloud infrastructure and application services that allow you to uniquely and securely combine cloud busi...
SYS-CON Events announced today that Akana, formerly SOA Software, has been named “Bronze Sponsor” of SYS-CON's 16th International Cloud Expo® New York, which will take place June 9-11, 2015, at the Javits Center in New York City, NY. Akana’s comprehensive suite of API Management, API Security, Integrated SOA Governance, and Cloud Integration solutions helps businesses accelerate digital transformation by securely extending their reach across multiple channels – mobile, cloud and Internet of Thi...
Businesses are looking to empower employees and departments to do more, go faster, and streamline their processes. For all workers – but mobile workers especially – utilizing the cloud to reconnect documents and improve processes without destructing existing workflows can have a dramatic impact on productivity. In his session at 16th Cloud Expo, Mark Grilli, vice president of Acrobat Solutions marketing at Adobe Systems Incorporated, will outline new ways that the cloud is changing the way peo...
SYS-CON Events announced today that Vitria Technology, Inc. will exhibit at SYS-CON’s @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Vitria will showcase the company’s new IoT Analytics Platform through live demonstrations at booth #330. Vitria’s IoT Analytics Platform, fully integrated and powered by an operational intelligence engine, enables customers to rapidly build and operationalize advanced analytics to deliver timely business outcomes ...